At Medicard we value what makes you unique. Be part of a company that thinks differently to solve problems, make progress and deliver meaningful innovations.

If you wants to be part of our team you should be able to:

• Promote the company image and the one of the company portfolio products, in private and state hospitals.
• Organize scientific events, conferences, symposiums and others.
• As a products expert, you understand what surgeons and their teams need.
• Ensure that our products and supporting services are properly understood by the doctors and available patients.

Apply if you have:

• University degree in any discipline, preferably in biomedical science/engineering or nursing.
• At least two years of relevant experience
• Excellent spoken and written English.
• Ability to travel.
• Driving license.

We offer:

• Potential further personal and professional growth.
• Many employees benefits.
• Flexible work environment.

 

Единствената терапия за това социалнозначимо заболяване е епилептичната хирургия. Кетогенната диета може да намали пристъпите, но да се прилага под строг контрол.

Епилепсията е световен медико-социален проблем. Около 50 млн. души в света страдат от болестта. Тя е най-честото хронично неврологично заболяване – засяга 5-10 на 1000 души.

Прочети повече

Годишната среща на EACTS ще се състои на 14-16.10.2021г. в Барселона, Испания.

Thirteen years of Perceval clinical results presented at the 35th European Association for Cardio-Thoracic Surgery Annual Meeting

New data underline highly favorable early and long-term outcomes.

New clinical evidence on Perceval has been presented at the 35th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting.

In particular, Dr Lamberigts presented the experience of the University Hospital in Leuven that has recently reached 1,000 Perceval implants. The data presented at the congress are the result of a retrospective study conducted from 2007 to 2020 to analyse the outcomes of 785 intermediate risk patients implanted with Perceval.

These data, coming from a real-world experience, confirm that Perceval, the only truly sutureless surgical valve, can be successfully used in various surgical settings with early and long-term positive outcomes.
In terms of early results, the presentation reported
lower than expected observed mortality: 1.4% in isolated aortic valve replacements and 4.5% in concomitant procedures
low incidence of stroke: 1.8 %
low permanent pacemaker implant with new sizing procedure introduced in 2017: 4.6%
The population was averagely followed up for 7.3 years and showed
low rate of Structural Valve Deterioration (SVD) and of reintervention for SVD: respectively 0.76% and 0.5%
low rate of reintervention: 1.9%
stable hemodynamics with low rate of paravalvular leak

With the first implant in-human dated 2007 and more than 75,000 patients treated worldwide, new long-term data confirm that Perceval is a reliable and essential technology within the modern therapeutic armamentarium to treat aortic valve disease, by offering patients an advanced and safe surgical option.